Gavin C. Hirst

Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck: a selectivity insight

A series of para-substituted 3-phenyl pyrazolopyrimidines was synthesized and evaluated as inhibitors of lck. The nature of the substitution affected enzyme selectivity and potency for lck, src, kdr, and tie-2. The para-phenoxyphenyl analogue 2 is an orally active lck inhibitor with a bioavailability of 69% and exhibits an extended duration of action in animal models of T cell inhibition.

Fragment-based discovery of JAK-2 inhibitors.

Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor.

Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists.

A novel series of cyanoguanidine-piperazine P2X(7) antagonists were identified and structure-activity relationship (SAR) studies described. Compounds were assayed for activity at human and rat P2X(7) receptors in addition to their ability to inhibit IL-1 beta release from stimulated human whole blood cultures. Compound 27 possesses potent activity (0.12 microM) in this latter assay and demonstrates moderate clearance in-vivo.

Conversion of acyclic nonpeptide CCK antagonists into CCK agonists

Abstract The CCK antagonists RP 69758 and ( R )-lorglumide were converted into CCK agonists by the introduction of an N -isopropylanilide agonist “trigger.” The common structural features of these ligands suggest that nonpeptide agonists and antagonists bind to a common site in the CCK receptor.